spebrutinib

08/01/2013 - "These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease. "

08/01/2013 - "These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease. "

04/07/2021 - "However, neither CC-292 alone nor its use in combination with mechanical loading was more effective in reducing osteolytic bone disease or rescuing bone mass than mechanical stimuli alone, as evidenced by microcomputed tomography (microCT) and histomorphometric analysis. "
04/07/2021 - "Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease."
09/01/2014 - "These results suggest that CC-292 combined with carfilzomib augments the inhibitory effects against OC within the bone microenvironment and has promising therapeutic potential for the treatment of MM and related bone disease. "

01/27/2017 - "Most of these inhibitors displayed improved activity against B leukemia cell lines compared with lead compound spebrutinib. "

01/01/2019 - "In in vivo studies using the adoptive transfer TCL1 mouse model of CLL, CC-292 reduced tumor load and normalized tumor-associated expansion of T cells and monocytes, while not affecting T cell function. "
01/01/2023 - "In particular, 14m had IC50 values 101-1045 times lower than those of spebrutinib against all cancer cell lines tested. "
01/01/2019 - "In addition, 30ab displays stronger selectivity on B-cell lymphoma over other cancer cell lines than spebrutinib. "
10/01/2017 - "CC-292, a potent Bruton tyrosine kinase inhibitor, is under development for the treatment of B-cell malignancies. "
09/01/2014 - "Moreover, the combination treatment in an in vivo MM mouse model inhibited tumor burden compared with CC-292 alone; it also increased bone volume compared with carfilzomib alone. "